Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients
Clinical trial NCT02253277 · COMPLETED
Trial details
- NCT number
- NCT02253277
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-18
- Primary completion
- 2018-03-06
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.